- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.12. | Vincerx Pharma, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 04.12. | Vincerx Pharma, Inc.: Vincerx Pharma to Implement Cost-Controls to Support Advancing Phase 1 Study of VIP943 | 112 | GlobeNewswire (Europe) | PALO ALTO, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting... ► Artikel lesen | |
| VINCERX PHARMA Aktie jetzt für 0€ handeln | |||||
| 25.11. | Vincerx Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.11. | Vincerx Pharma GAAP EPS of -$0.17 | 1 | Seeking Alpha | ||
| 12.11. | Vincerx Pharma, Inc.: Vincerx Pharma Reports Third Quarter 2024 Financial Results | 105 | GlobeNewswire (Europe) | Continued enrollment and dose escalation in Phase 1 study of VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC); additional data expected by early 2025 Completed Phase... ► Artikel lesen | |
| 12.11. | Vincerx Pharma, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 12.11. | Vincerx Pharma, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 08.10. | Penny Stock Cancer-Focused Vincerx Pharma Seeks Development Partner For 2 Early-Stage Blood Cancer Candidates | 17 | Benzinga.com | ||
| 08.10. | Vincerx stock tumbles 20% on corporate updates | 10 | Seeking Alpha | ||
| 08.10. | Leerink senkt Kursziel für Vincerx Pharma nach Pipeline-Update | 13 | Investing.com Deutsch | ||
| 08.10. | Leerink cuts Vincerx Pharma stock target on pipeline update | 3 | Investing.com | ||
| 08.10. | Vincerx Reports Positive Initial Clinical Data From VIP943 Phase 1 Dose-Escalation Study | 5 | RTTNews | ||
| 07.10. | Vincerx Pharma, Inc.: Vincerx Reports Positive Initial Clinical Data from Ongoing VIP943 Phase 1 Dose-Escalation Study and Provides Pipeline and Corporate Updates | 103 | GlobeNewswire (Europe) | VIP943 demonstrates promising safety and tolerability and achieves two complete responses to date in Phase 1 dose-escalation study, reinforcing the program's potential and validating the VersAptx... ► Artikel lesen | |
| 16.08. | Vincerx Pharma, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 09.08. | Vincerx Pharma GAAP EPS of -$0.05 | 3 | Seeking Alpha | ||
| 08.08. | Vincerx Pharma, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 08.08. | Vincerx Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.08. | Vincerx Pharma, Inc.: Vincerx Pharma Reports Second Quarter 2024 Financial Results | 91 | GlobeNewswire (Europe) | Vincerx continues to enroll its Phase 1 studies of antibody-drug conjugate (ADC) VIP943, with data expected by the end of Q4 2024, and small molecule drug-conjugate (SMDC) VIP236, with data expected... ► Artikel lesen | |
| 14.05. | Vincerx Pharma, Inc.: Vincerx Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update | 204 | GlobeNewswire (Europe) | Vincerx continued to progress Phase 1 dose-escalation studies for VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC), and VIP236, a first-in-class small molecule-drug conjugate... ► Artikel lesen | |
| 08.04. | Vincerx Pharma, Inc.: Vincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024 | 145 | GlobeNewswire (Europe) | VIP236 demonstrated positive signs of clinical activity, including tumor reduction, and an improved safety profile in heavily pretreated patients with metastatic solid tumors VIP943 pharmacokinetic... ► Artikel lesen |
Seite:
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ASTRIA THERAPEUTICS | 9,000 | -1,64 % | Astria Therapeutics, Inc. - 8-K, Current Report | ||
| ROCKET LAB USA | 24,700 | +0,41 % | Space Technology: Rocket Lab stellt zweites Raumfahrzeug für Varda Space Industries fertig | ||
| BOIRON | 26,300 | +3,75 % | BOIRON: EVOLUTION OF GOVERNANCE | July 3rd, 2024
The Board of Directors of Laboratoires BOIRON, meeting today under the chairmanship of Thierry BOIRON, has enacted an evolution of the Group's governance.
In this context, Thierry... ► Artikel lesen | |
| HARROW | 33,450 | 0,00 % | Harrow Health Aktie: Stabile Aussichten? | Der Aktienkurs des Augenheilkunde-Spezialisten Harrow Health verzeichnete am 07. Dezember einen bemerkenswerten Anstieg von 5,08 Prozent auf 39,32 USD. Die Entwicklung steht im Kontrast zum negativen... ► Artikel lesen | |
| ESSA PHARMA | 1,620 | 0,00 % | ESSA Pharma Inc: ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2024 | Company has initiated a process to explore and review strategic options focused on maximizing shareholder value
SOUTH SAN FRANCISCO, California and VANCOUVER... ► Artikel lesen | |
| MEDICINOVA | 2,020 | 0,00 % | MediciNova, Inc.: MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND | LA JOLLA, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 3,515 | 0,00 % | Aquestive receives FDA Orphan Drug Exclusivity for Libervant | ||
| LYRA THERAPEUTICS | 0,169 | 0,00 % | Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update | Company continues to focus on upcoming results from ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients expected in 2Q 2025 Company reports topline safety results from ENLIGHTEN 1 Phase 3 extension... ► Artikel lesen | |
| CUMBERLAND PHARMACEUTICALS | 2,520 | 0,00 % | Cumberland Pharmaceuticals Inc.: FDA Approves Acetadote sNDA | - New Dosing Regimen Simplifies Administration -
NASHVILLE, Tenn., Dec. 9, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty... ► Artikel lesen | |
| REVIVA PHARMACEUTICALS | 1,795 | 0,00 % | Reviva Pharmaceuticals: Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights | - 108 patients have completed 1-year of treatment in 1-year open-label extension (OLE) trial - - Vocal biomarker speech latency data from RECOVER trial reinforce brilaroxazine's improvement on negative... ► Artikel lesen | |
| CYANOTECH | 0,260 | 0,00 % | Cyanotech Reports Financial Results for the Second Quarter and First Six Months of Fiscal 2025 | KAILUA KONA, Hawaii--(BUSINESS WIRE)--Cyanotech Corporation (OTCQB: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results... ► Artikel lesen | |
| NUTRIBAND | 3,840 | -4,95 % | Nutriband Inc. Quarterly Report Highlights Record Revenue for Q3 up 50.94% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl in 2025 | ORLANDO, Fla., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) today reported its financial results for the third quarter ended October 31, 2024. The Company reported... ► Artikel lesen | |
| ONKURE THERAPEUTICS | 7,890 | 0,00 % | Reneo Pharmaceuticals-Aktie erreicht 52-Wochen-Tief bei 7,91 US-Dollar | ||
| PROCESSA PHARMACEUTICALS | 0,862 | 0,00 % | Processa Pharmaceuticals, Inc. - S-1, General form for registration of securities |
VINCERX PHARMA INC gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 0,185 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VINCERX PHARMA INC finden Sie auf Wallstreet Online.
